Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12241MR)

This product GTTS-WQ12241MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12241MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2410MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ103MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ7814MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ4685MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ11568MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ5272MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ10938MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ10969MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW